Detailed Narrative
Q3 & 9M FY26 Strong Financial Performance
CORONA Remedies reported robust financial results for Q3 FY26, with revenue growing 15% YoY to ₹342 crores and EBITDA increasing 20% to ₹83 crores, leading to a 100 bps margin expansion to 24.3%. For the nine months ended December 31, 2025, revenue reached ₹1,050 crores, up 16% YoY, and EBITDA grew 25% to ₹231 crores, with margin improving by 140 bps to 22%. Adjusted PAT for 9M FY26 stood at ₹154 crores, reflecting a significant 31% YoY growth, demonstrating strong operational efficiency.
Market Leadership and Outperformance
The company achieved the #1 fastest-growing pharmaceutical company position among the top 30 in India for Q3 FY26, with an 18.9% growth rate, nearly double the Indian Pharmaceutical Market's (IPM) 9.6%. This strong performance propelled CORONA two ranks up, from 30th to 28th in the IPM. Management highlighted that this growth is primarily volume-driven, supported by the company's strategic focus on chronic and semi-chronic therapeutic segments, which contribute 70%-72% of total revenue.
Strategic Acquisitions and International Expansion
CORONA continues to execute strategic brand acquisitions, including several from Bayer in July 2025, with the commercialization of the antiplatelet brand Noklot Plus slated for Q4 FY26. The company also plans to launch 4-5 brands within the IVF portfolio. Furthermore, the Gujarat facility received EU GMP and Eurasian GMP accreditation, enabling market entry into five EAEU member countries and aligning with the long-term vision of strengthening international partnerships.
Capital Allocation and Self-Funded Growth
The company maintains a strong financial position, being net cash positive with over ₹100 crores and achieving an 86% OCF to EBITDA conversion for 9M FY26. Management confirmed that internal cash generation is sufficient to fund international business expansion, negating the need for additional external capital. A 600 kg line was capitalized, enhancing capacity by 40%, and plans for another plant in FY28-FY29 are being considered.
Future Growth Strategy and Product Pipeline
CORONA aims for an annual revenue growth of 15% and PAT growth of 20%, driven by a strategy of launching 8-10 new products per year. This includes entering new therapeutic areas like infertility and rheumatology. Upcoming launches include the GLP-1 injectable (Wyntide) in Q4 FY26, 4-5 brands in the IVF portfolio, and three biosimilars (Denosumab, recombinant FSH) in Q4 FY26, targeting specialist and super-specialist prescribers.
Margin Outlook and Operating Leverage
Management anticipates continued EBITDA margin improvement, targeting the high 20s or 30% in the medium to long term. This improvement is expected to stem from operating leverage, as the significant investment in deploying 600 medical representatives over the past three years begins to yield higher productivity and improved Per Capita Per Month (PCPM). The company's commitment to 15% revenue growth is expected to further support margin expansion.
Minimal Business Seasonality
Due to its product mix, with 70-72% of its business in chronic and semi-chronic segments, CORONA experiences minimal seasonality. Management indicated that quarter-on-quarter revenue variations are typically limited to a 3-4% fluctuation. Expenses are strategically staggered throughout the year, ensuring consistent profitability and avoiding significant load in any single quarter, contributing to overall business stability.